Cargando…

CRISPR-Cas9 Library Screening Identifies Novel Molecular Vulnerabilities in KMT2A-Rearranged Acute Lymphoblastic Leukemia

In acute lymphoblastic leukemia (ALL), chromosomal translocations involving the KMT2A gene represent highly unfavorable prognostic factors and most commonly occur in patients less than 1 year of age. Rearrangements of the KMT2A gene drive epigenetic changes that lead to aberrant gene expression prof...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schneider, Pauline, Wander, Priscilla, Arentsen-Peters, Susan T. C. J. M., Vrenken, Kirsten S., Rockx-Brouwer, Dedeke, Adriaanse, Fabienne R. S., Hoeve, Veerle, Paassen, Irene, Drost, Jarno, Pieters, Rob, Stam, Ronald W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487613/ https://www.ncbi.nlm.nih.gov/pubmed/37686014 http://dx.doi.org/10.3390/ijms241713207

Ejemplares similares

Modelling acquired resistance to DOT1L inhibition exhibits the adaptive potential of KMT2A-rearranged acute lymphoblastic leukemia
por: Schneider, Pauline, et al.
Publicado: (2023)

High-Throughput Drug Library Screening in Primary KMT2A-Rearranged Infant ALL Cells Favors the Identification of Drug Candidates That Activate P53 Signaling
por: Wander, Priscilla, et al.
Publicado: (2022)

Preclinical Evaluation of Carfilzomib for Infant KMT2A-Rearranged Acute Lymphoblastic Leukemia
por: Cheung, Laurence C., et al.
Publicado: (2021)

Irinotecan Induces Disease Remission in Xenograft Mouse Models of Pediatric MLL-Rearranged Acute Lymphoblastic Leukemia
por: Kerstjens, Mark, et al.
Publicado: (2021)

Identification and characterization of relapse-initiating cells in MLL-rearranged infant ALL by single-cell transcriptomics
por: Candelli, Tito, et al.
Publicado: (2021)

Updates in KMT2A Gene Rearrangement in Pediatric Acute Lymphoblastic Leukemia
por: Górecki, Mateusz, et al.
Publicado: (2023)

B‐cell lymphoblastic lymphoma with cutaneous involvement and a KMT2A gene rearrangement
por: Kemps, Paul G., et al.
Publicado: (2020)

Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience
por: Richard-Carpentier, Guillaume, et al.
Publicado: (2021)

In vitro Modeling of Embryonal Tumors
por: Custers, Lars, et al.
Publicado: (2021)

Clinical Implications of Minimal Residual Disease Detection in Infants With KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol
por: Stutterheim, Janine, et al.
Publicado: (2021)

Lineage switch from B lymphoblastic leukemia with KMT2A-rearranged to mixed-phenotype acute leukemia under daratumumab
por: Marco-Ayala, Javier, et al.
Publicado: (2020)

Editorial: Harnessing chemotherapy resistance and development of novel therapeutic strategies for acute leukemia with KMT2A (MLL)-gene rearrangements
por: Esposito, Maria Teresa, et al.
Publicado: (2022)

XRCC4 rs28360071 intronic variant is associated with increased risk for infant acute lymphoblastic leukemia with KMT2A rearrangements
por: Louzada-Neto, Orlando, et al.
Publicado: (2020)

Poor treatment responses were related to poor outcomes in pediatric B cell acute lymphoblastic leukemia with KMT2A rearrangements
por: Wen, Jinquan, et al.
Publicado: (2022)

Case Report: Rare IKZF1 Gene Fusions Identified in Neonate with Congenital KMT2A-Rearranged Acute Lymphoblastic Leukemia
por: Eadie, Laura N., et al.
Publicado: (2023)

Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy
por: Cheung, Laurence C., et al.
Publicado: (2022)

Single-cell transcriptomics reveals a distinct developmental state of KMT2A-rearranged infant B-cell acute lymphoblastic leukemia
por: Khabirova, Eleonora, et al.
Publicado: (2022)

Effective tumor cell abrogation via Venetoclax-mediated BCL-2 inhibition in KMT2A-rearranged acute B-lymphoblastic leukemia
por: Richter, Anna, et al.
Publicado: (2022)

Combined BCL-2 and PI3K/AKT Pathway Inhibition in KMT2A-Rearranged Acute B-Lymphoblastic Leukemia Cells
por: Holz, Clemens, et al.
Publicado: (2023)

MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations
por: Kerstjens, Mark, et al.
Publicado: (2016)

Systematic In Vitro Evaluation of a Library of Approved and Pharmacologically Active Compounds for the Identification of Novel Candidate Drugs for KMT2A-Rearranged Leukemia
por: Karsa, Mawar, et al.
Publicado: (2022)

Pan-sarcoma genomic analysis of KMT2A rearrangements reveals distinct subtypes defined by YAP1–KMT2A–YAP1 and VIM–KMT2A fusions
por: Massoth, Lucas R., et al.
Publicado: (2020)

Dysregulated transcriptional networks in KMT2A- and MLLT10-rearranged T-ALL
por: Kang, Huining, et al.
Publicado: (2018)

Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements
por: Issa, Ghayas C., et al.
Publicado: (2021)

Novel Diagnostic and Therapeutic Options for KMT2A-Rearranged Acute Leukemias
por: Lopes, Bruno A., et al.
Publicado: (2022)

PB1799: KMT2A-REARRANGED PEDIATRIC ACUTE MYELOID LEUKEMIA
por: Zerkalenkova, E., et al.
Publicado: (2022)

Identification of Genes Transcriptionally Responsive to the Loss of MLL Fusions in MLL-Rearranged Acute Lymphoblastic Leukemia
por: van der Linden, Marieke H., et al.
Publicado: (2015)

The Partial Duplication of the 5′ Segment of KMT2A Revealed KMT2A-MLLT10 Rearrangement in a Boy with Acute Myeloid Leukemia
por: Fukushima, Hiroko, et al.
Publicado: (2017)

Drug Repurposing for Targeting Acute Leukemia With KMT2A (MLL)—Gene Rearrangements
por: Tsakaneli, Alexia, et al.
Publicado: (2021)

KMT2A-CBL rearrangements in acute leukemias: clinical characteristics and genetic breakpoints
por: Bataller, Alex, et al.
Publicado: (2021)

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia
por: Issa, Ghayas C., et al.
Publicado: (2023)

Decitabine mildly attenuates MLL‐rearranged acute lymphoblastic leukemia in vivo, and represents a poor chemo‐sensitizer
por: Schneider, Pauline, et al.
Publicado: (2020)

Proteasome inhibition targets the KMT2A transcriptional complex in acute lymphoblastic leukemia
por: Kamens, Jennifer L., et al.
Publicado: (2023)

Normal and tumor-derived organoids as a drug screening platform for tumor-specific drug vulnerabilities
por: Calandrini, Camilla, et al.
Publicado: (2022)

Dysregulation of the DNA Damage Response and KMT2A Rearrangement in Fetal Liver Hematopoietic Cells
por: Nanya, Mai, et al.
Publicado: (2015)

Impact of KMT2A Rearrangement and CSPG4 Expression in Pediatric Acute Myeloid Leukemia
por: Hoffmeister, Lina Marie, et al.
Publicado: (2021)

PAX5 alterations in an infant case of KMT2A‐rearranged leukemia with lineage switch
por: Nakajima, Koji, et al.
Publicado: (2022)

Frequency and prognostic implications of KMT2A rearrangements in children with precursor B-cell lymphoma
por: Au-Yeung, Rex K. H., et al.
Publicado: (2022)

Palbociclib in Acute Leukemias With KMT2A-rearrangement: Results of AMLSG 23-14 Trial
por: Gaidzik, Verena I., et al.
Publicado: (2023)

Monocytic and blastic plasmacytoid dendritic cell differentiation in acute leukemia with KMT2A rearrangement
por: Xue, Owen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_di30v6ak1q1nita3bigcj2vfuv